* Anchored Note, page 1
chromosome conformation capture (3C) (Dekker et al. 2002)

-PXh(Dekker et al 2002)

* Anchored Note, page 2
<!>5-Bromo-4-chloro-3-indoyl-β-D-galactopyranoside (X-gal; 25 mg/mL in DMF [dimethylformamide])

-PAh(Appendix)

* Anchored Note, page 2
<R>Bead eluting buffer

-PRh(Appendix)

* Anchored Note, page 2
<R>Cellular lysis solution

-PRh(Appendix)

* Anchored Note, page 2
<R>ChIP diluent

-PRh(Appendix)

* Anchored Note, page 2
<!>DNA gel stain (SYBR Safe, 10,000X concentrate in DMSO [dimethylsulfoxide]; Invitrogen)

-PAh(Appendix)

* Anchored Note, page 2
<!>Formaldehyde solution (≥36.5%; Sigma-Aldrich 33220)

-PAh(Appendix)

* Anchored Note, page 2
<R>Immune complex wash buffers (high-salt and low-salt) Prepare the high-salt and low-salt versions of this buffer separately

-PRmh(Appendix)

* Anchored Note, page 2
<!>Isopropyl-β-D-thiogalactopyranoside (IPTG; 200 mg/mL)

-PAh(Appendix)

* Anchored Note, page 2
<R>LB agar

-PRh(Appendix)

* Anchored Note, page 2
<R>LB-ampicillin agar plates

-PRh(Appendix)

* Anchored Note, page 2
<R>Alternatively, LB-kanamycin agar plates can be used (see Step 48).

-PRh(Appendix)

* Anchored Note, page 2
<R>LB (Luria-Bertani) liquid medium

-PRh(Appendix)

* Anchored Note, page 2
<R>Ligation buffer (10X)

-PRh(Appendix)

* Anchored Note, page 2
<!>Phenol:chloroform:isoamyl alcohol, UltraPure (25:24:1 v/v/v; Invitrogen)

-PAh(Appendix)

* Anchored Note, page 2
<!>Proteinase K (10 mg/mL in TE buffer, pH 8.0; Invitrogen)

-PAh(Appendix)

* Anchored Note, page 3
<!>RNase A, DNase-free (10 mg/mL; Sigma R6513)

-PAh(Appendix)

* Anchored Note, page 3
<R><!>SDS (Sodium dodecyl sulfate; 20% w/v; Fisher BP166)

-PAh(Appendix)

* Anchored Note, page 3
<R><!>SDS (Sodium dodecyl sulfate; 20% w/v; Fisher BP166)

-PRh(Appendix)

* Anchored Note, page 3
<R>Sodium acetate (3 M, pH 5.2; Fisher BP333)

-PRh(Appendix)

* Anchored Note, page 3
<R>TE buffer (pH 8.0)

-PRh(Appendix)

* Anchored Note, page 3
<!>Triton X-100 (20% v/v; VWR)

-PAh(Appendix)

* Anchored Note, page 3
<!>Trypsin (1X; Invitrogen 25300)

-PAh(Appendix)

* Anchored Note, page 3
<!>Liquid nitrogen (optional; see Step 11)

-PAh(Appendix)

* Anchored Note, page 3
<!>UV light

-PAh(Appendix)

* Anchored Note, page 7
Using standard cloning protocols, clone the 3C-ChIP products (from Step 44) into a vector that has enzyme overhangs similar to those generated in the 3C assay. This step typically involves cloning an “IgG/no antibody 3C-ChIP product” and “Plus antibody 3C-ChIP prod- uct,” in addition to regular cloning controls.

-LBm

* Anchored Note, page 7
Purify the plasmids using the PureLink HQ 96 Mini Plasmid DNA Purification Kit according to the manufacturer’s instructions.

-MBh(PureLink HQ 96 Mini Plasmid DNA Purification Kit Mfr. Instr)

* Anchored Note, page 7
. Screen the purified plasmids (from Step 52) by digestion with the same restriction enzyme used for Step 16, using standard restriction digestion protocols.

-LB

* Anchored Note, page 7
hould be validated by performing independent 3C assays (Tolhuis et al. 2002)

-PSh(Tolhuis et al 2002)

* Anchored Note, page 7
The primers for this purpose are designed exactly as described by Splinter et al. (2004)

-PXh(Splinter et al 2004)

* Anchored Note, page 7
perform ChIP assays (Tiwari et al. 2008)

-PSh(Tiwari et al 2008)

* Anchored Note, page 8
Following immunopre- cipitation with the antibody of interest, the samples can be subjected to 4C analysis (Zhao et al. 2006)

-PSh(Zhao et al 2006)

* Anchored Note, page 8
reverse-cross-linked, purified, digested with a four-cutter enzyme of choice, and processed further for either 3C-chip (Simonis et al. 2006)

-PSh(Simonis et al 2006)

* Anchored Note, page 8
or the ACT assay (Ling et al. 2006).

-PSh(2006)

* Anchored Note, page 8
following the amplification criteria used in the original 3C assay, subsequent to the reversal of cross-linking and purification (Dekker et al. 2002).

-PSh(Dekker et al 2002)

